Patent: 7,476,389
✉ Email this page to a colleague
Summary for Patent: 7,476,389
| Title: | Papillomavirus vaccines |
| Abstract: | A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in related to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or the combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs. |
| Inventor(s): | Ian Frazer, Jian Zhou |
| Assignee: | University of Queensland UQ , CSL Ltd |
| Application Number: | US08/185,928 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,476,389
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | GARDASIL 9 | human papillomavirus 9-valent vaccine, recombinant | Injection | 125508 | December 10, 2014 | ⤷ Start Trial | 2026-01-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,476,389
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | E234925 | ⤷ Start Trial |
| Austria | E332973 | ⤷ Start Trial |
| Austria | E356142 | ⤷ Start Trial |
| Australia | 2366692 | ⤷ Start Trial |
| Australia | 651727 | ⤷ Start Trial |
| Canada | 2113712 | ⤷ Start Trial |
| Cyprus | 2007015 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
